KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2025)

Historic Debt to Equity for Adaptive Biotechnologies (ADPT) over the last 4 years, with Q3 2025 value amounting to $0.64.

  • Adaptive Biotechnologies' Debt to Equity rose 874.82% to $0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.64, marking a year-over-year increase of 874.82%. This contributed to the annual value of $0.66 for FY2024, which is 5518.83% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Debt to Equity of $0.64 as of Q3 2025, which was up 874.82% from $0.74 recorded in Q2 2025.
  • Adaptive Biotechnologies' Debt to Equity's 5-year high stood at $0.74 during Q2 2025, with a 5-year trough of $0.27 in Q4 2022.
  • In the last 4 years, Adaptive Biotechnologies' Debt to Equity had a median value of $0.57 in 2024 and averaged $0.54.
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 6510.65% in 2024, then skyrocketed by 874.82% in 2025.
  • Adaptive Biotechnologies' Debt to Equity (Quarter) stood at $0.27 in 2022, then skyrocketed by 56.87% to $0.42 in 2023, then skyrocketed by 55.19% to $0.66 in 2024, then dropped by 1.92% to $0.64 in 2025.
  • Its last three reported values are $0.64 in Q3 2025, $0.74 for Q2 2025, and $0.7 during Q1 2025.